Market Overview

Akebia Therapeutics Rocket 48 Percent Higher on First Day of Trading

Related AKBA
Akebia Presents Positive Vadadustat Phase 2 Dialysis Data at American Society of Nephrology Kidney Week 2015 Annual Meeting
Akebia Reaches Agreement with FDA and EMA on Vadadustat Global Phase 3 Program

Shares of Akebia Therapeutics (NASDAQ: AKBA) are rocketing up 48 percent to $25.25 in its first day of trading.

Shares opened at 10:57 a.m. EDT on Thursday for $22.90 per share.

The company raised $100.3 million after 5.9 million shares were priced at $17 per share, significantly above the initial range of $14-$17.

Akebia is a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease.

Morgan Stanley and Credit Suisse were the lead underwriters for the offering.

Posted-In: Credit Suisse Morgan StanleyNews IPOs


Related Articles (AKBA)

View Comments and Join the Discussion!

Get Benzinga's Newsletters